Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
Event to Feature Renowned Gastroenterologist Dr. David Rubin
Highlighting the Ulcerative Colitis Treatment Landscape and Abivax’s Pivotal ABTECT Phase 3 Trial
PARIS, France – February 21, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, today announced it will host a Key Opinion Leader (KOL) Investor Webcast on Monday, March 17, 2025, at 9:00 a.m. EDT (2:00 p.m. CET).
The webcast will feature Dr. David Rubin, a renowned gastroenterologist, who will discuss the current landscape of ulcerative colitis treatment and provide insights into Abivax’s pivotal ABTECT Phase 3 trial. This trial aims to evaluate the efficacy and safety of ABX464, a novel drug candidate developed by Abivax for the treatment of ulcerative colitis.
Ulcerative colitis is a chronic inflammatory bowel disease that affects the colon and rectum, causing symptoms such as abdominal pain, diarrhea, and rectal bleeding. Current treatment options for ulcerative colitis include anti-inflammatory medications, immunosuppressants, and biologics, but many patients fail to achieve remission or experience significant side effects.
ABX464 is a potential game-changer in the field of ulcerative colitis treatment, as it offers a novel mechanism of action that targets inflammation at the cellular level. The results of the ABTECT Phase 3 trial could have a significant impact on the treatment landscape for patients with ulcerative colitis and provide new hope for those who have not responded to current therapies.
How Will This Impact Me?
As a patient with ulcerative colitis, the results of the ABTECT Phase 3 trial could potentially offer you a new treatment option that is more effective and better tolerated than current therapies. If ABX464 is successful in clinical trials, it could revolutionize the way ulcerative colitis is treated and improve outcomes for patients like you.
How Will This Impact the World?
If ABX464 proves to be effective in treating ulcerative colitis, it could have a significant impact on the global healthcare landscape. By providing a new, innovative treatment option for patients with chronic inflammatory diseases, Abivax’s research has the potential to improve the quality of life for millions of people worldwide and advance the field of biotechnology.
Conclusion
In conclusion, the Key Opinion Leader webcast hosted by Abivax on March 17, 2025, featuring renowned gastroenterologist Dr. David Rubin, promises to shed light on the current treatment landscape for ulcerative colitis and provide key insights into Abivax’s groundbreaking ABTECT Phase 3 trial. The potential success of ABX464 in treating ulcerative colitis could have far-reaching implications for patients and the global healthcare community, offering new hope and improved outcomes in the fight against chronic inflammatory diseases.
